Xtant Medical Holdings Inc  

(Public, NYSEMKT:XTNT)   Watch this stock  
Find more results for NYSEAMEX:BONE
0.00 (0.00%)
Feb 9 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 2.10 - 2.25
52 week 2.02 - 4.50
Open 2.20
Vol / Avg. 3,753.00/11,986.00
Mkt cap 25.28M
P/E     -
Div/yield     -
EPS -2.17
Shares 11.89M
Beta 1.91
Inst. own 13%
May 3, 2016
Q1 2016 Xtant Medical Holdings Inc Earnings Release (Estimated) Add to calendar
Feb 10, 2016
Xtant Medical Holdings Inc at Source Capital Group Disruptive Growth & Healthcare Conference - 10:15AM EST - Add to calendar
Jan 12, 2016
Q4 2015 Xtant Medical Holdings Inc Earnings Release
Dec 2, 2015
Xtant Medical Holdings Inc at LD Micro Main Event Conference
Nov 12, 2015
Q3 2015 Xtant Medical Holdings Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -37.81% -29.74%
Operating margin -27.61% -17.73%
EBITD margin - -12.45%
Return on average assets -35.17% -36.98%
Return on average equity - -
Employees 150 -
CDP Score - -


664 Cruiser Ln
BELGRADE, MT 59714-9719
United States - Map
+1-406-3880480 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Bacterin International Holdings, Inc. is engaged in developing, manufacturing and marketing biologics products to domestic and international markets. The Company's bone graft products are used in a range of applications, including enhancing fusion in spine surgery, relief of back pain through facet joint stabilization, promotion of bone growth in foot and ankle surgery, promotion of skull healing following neurosurgery and subchondral bone repair in knee and other joint surgeries. The Company's acellular dermis scaffolds are utilized in wound care and plastic and reconstructive procedures. The Company also develops custom surgical instruments for use with its allografts. The Company's products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoWrap, OsteoLock, BacFast HD, OsteoSTX, hMatrix and its line of 3Demin products, as well as other allograft products.

Officers and directors

Kent L. Swanson Independent Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Daniel S. Goldberger Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
John P. Gandolfo Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Darrel Lee Holmes Chief Operating Officer
Age: 62
Bio & Compensation  - Reuters
Gregory Juda Ph.D. Chief Scientific Officer
Age: 39
Bio & Compensation  - Reuters
John Deedrick Independent Director
Age: 52
Bio & Compensation  - Reuters
David E. Goodman M.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Michael A. Lopach CPA Independent Director
Age: 66
Bio & Compensation  - Reuters
Jon M. Wickwire Independent Director
Age: 71
Bio & Compensation  - Reuters